How long do ibogaine's effects last?

This question has four answers, and they differ by orders of magnitude. The drug is largely gone within a day [2]. The heart effect can outlast a week [2]. The experience runs twelve to twenty-eight hours [6]. The behavioural changes reported in follow-up studies have been measured out to twelve months [3].

Four questions, not one

Most confusion about ibogaine's duration comes from treating these as a single question. They are not related in the way intuition suggests, and the gaps between them are the most interesting thing about the compound.

A conventional drug's effects track its presence. Ibogaine's reported effects do not, which is why its mechanism has stayed unresolved for decades [1].

Separating the four also matters practically. The timescale that determines when someone is medically safe is not the one that determines how long they might feel different.

The four also carry very different weights of evidence, which is easy to lose when they appear in one sentence. How long the drug stays has been measured directly in blood samples. How long the heart effect lasts has been measured by EKG in monitored cohorts. How long the experience runs rests largely on observation. And how long the behavioural changes last rests on uncontrolled follow-up with people lost along the way.

Confidence should fall as the timescale lengthens. The first two figures are close to facts about pharmacology; the last is a reported pattern in small groups who also received other care.

How long the drug stays

More than ninety per cent of a dose is eliminated within twenty-four hours [2].

Ibogaine peaks roughly two hours after an oral dose of 500 to 1000 milligrams [2]. The body converts it to noribogaine, which peaks later, around two and a half hours, and does not decline significantly within the first twenty-four hours [2].

Noribogaine's own half-life has been measured at 28 to 49 hours in healthy volunteers and 24 to 30 hours in people dependent on opioids. So the metabolite is still circulating at a point when the parent compound has nearly gone.

That difference is the basis of the hypothesis that noribogaine carries the longer effects [1]. The rodent data complicates it: no appreciable noribogaine was found in brain tissue at nineteen hours, and serum levels at twenty-four hours were around five per cent of peak [1].

How long the heart effect lasts

This is the timescale that governs medical supervision, and it outlasts the drug.

QT prolongation after ibogaine typically lasts longer than twenty-four hours, and in some reported cases has persisted for more than a week [2].

The Dutch hospital data shows the same pattern in a monitored group. Six of fourteen patients still had a QT interval above 450 milliseconds beyond twenty-four hours [7].

Reported deaths cluster in this window rather than during the experience. Ibogaine-ascribed deaths occurred between about one and a half and seventy-six hours after intake in older cases, and twelve to twenty-four hours in more recent ones [2].

Someone who feels recovered on the second day is not therefore past the risk, and that mismatch is the single most practical thing on this page.

How long the experience runs

Intense effects begin one to three hours after the dose and last about four to eight hours, followed by a reflective state of roughly eight to twenty hours [6].

Insomnia often continues for about 72 hours afterwards and responds to sleep medication [6].

Loss of coordination tracks the drug itself rather than the subjective experience. In the Dutch cohort, ataxia correlated with ibogaine concentration, and all fourteen patients were unable to walk unaided [7].

How long withdrawal relief lasts

For opioid withdrawal, the reported timescale is hours to days rather than weeks.

In the New Zealand study, subjective withdrawal scores fell from 25.2 to 14.2 within twelve to twenty-four hours [3]. In the 1999 case series, withdrawal signs resolved within twenty-four hours without further drug administration [6].

Craving is reported to follow a longer course. In the 191-person St Kitts series, craving scores fell at discharge and remained lower at one month.

The distinction has a practical edge. Someone whose physical withdrawal resolved within a day may still face craving weeks later, and expecting otherwise turns an ordinary part of the course into evidence that something has failed.

These are different measures and should not be merged. Withdrawal is a physical syndrome with a timetable; craving is a subjective state that can return long afterwards.

What twelve-month follow-ups found

Two studies have followed people for a year, and they are the main basis for claims about durability.

The New Zealand study followed fourteen adults, of whom eight completed every interview and eleven remained at twelve months [3]. The drug-use composite score fell from 0.32 to 0.06 at twelve months, the only subscale with a significant drop, and depression scores fell from 22.1 to 4.4 [3]. The authors report reduced use or cessation in twelve of fourteen [3].

That study also recorded one death during treatment [3], which belongs in any summary of its findings.

The second is the Stanford follow-up, in which 25 of 30 veterans were reassessed at twelve months, with reductions in disability, PTSD, depression and anxiety holding across the year [4]. Estimated sustained remission at twelve months was 84 per cent for PTSD, 66 per cent for depression and 61 per cent for anxiety [4].

That follow-up is a preprint and has not been peer reviewed [4].

Months of abstinence in a records review

A Brazilian review of 75 clinic records offers a different measure, since it recorded time rather than scores.

Median self-reported abstinence was 5.5 months after a single treatment and 8.4 months after multiple treatments, both longer than those individuals had managed before their first session [5].

Treatment there combined ibogaine with psychotherapy [5], so the figure belongs to the combination. Most participants used several substances rather than one [5].

A median of 5.5 months is a useful corrective to both exaggerated and dismissive framings. It is considerably longer than the drug's presence, and it is not permanent.

A median also means half the group fell below it. Reporting a central figure without that reminder makes a range of outcomes sound like a single expected result, and the people below the median are as real as those above it.

Where aftercare fits in the timeline

Every study reporting durability included something beyond the dose, and the timing of that something follows a consistent pattern.

In the Brazilian review, ibogaine was combined with psychotherapy under a physician's supervision [5]. In the Stanford protocol, structured integration activities took place on day four, with therapist coaching before and after the session [4]. In New Zealand, treatment ran across 24 to 96 hours with staggered dosing and continued provider contact [3].

The common shape is that the drug occupies one day and the surrounding programme occupies considerably longer. Any claim about twelve-month outcomes is a claim about that whole arrangement.

This also explains why the weeks after treatment attract so much attention in the research. If something raises the capacity for change for a period, what fills that period determines what the change amounts to.

For a person planning treatment, the practical reading is that the calendar extends well beyond the session. The published durability figures come from people who had arrangements in place afterwards, and a treatment that ends at the airport is not the thing those numbers describe. The aftercare page covers what that period usually involves.

Why the durability is unexplained

The gap between a day of chemistry and a year of reported change is the central puzzle, and it remains open.

Receptor binding does not account for it: the 2019 review states that the receptor interactions do not seem to explain the long-lasting effects seen in rodents [1].

The growth-factor hypothesis proposes a self-sustaining loop that continues after the drug clears, which the same review describes as a rationale rather than a finding [1].

A third possibility is that part of the durability is not pharmacological at all. If a person stops using for several weeks, their circumstances, sleep, relationships and self-image change, and those changes have their own momentum.

What follow-up studies cannot show

None of the twelve-month findings comes from a controlled study, which limits what they establish.

Attrition shapes the numbers. Eight of fourteen completed every interview in New Zealand [3], and five of thirty were lost by twelve months at Stanford [4]. People who are doing badly are generally harder to reach, so remaining participants tend to be the better outcomes.

Self-report shapes them too. Abstinence in the Brazilian review was self-reported and gathered retrospectively [5].

And in every one of these studies, ibogaine came with something else: psychotherapy, aftercare, or an intensive programme. A year of reduced use after a package is not evidence about a molecule.

Relapse is the other side of the same question, and the follow-up studies describe it less clearly than they describe improvement. The Stanford paper notes that several participants had a recurrence of notable symptoms between assessment points, which means the smooth line implied by two data points was not everyone's experience. In the New Zealand cohort, twelve of fourteen reduced or stopped use [3], which leaves two who did not.

Those exceptions are not footnotes to the result. For a person deciding whether to pursue treatment, the probability of being among them is part of what they are deciding about, and a page reporting only the favourable fraction has answered a different question from the one being asked.

Where the research goes next

The honest position is that reported durability substantially exceeds the drug's presence, and the reason is not established.

Three things would clarify it. Controlled follow-up with a comparison group receiving equivalent surrounding care. Objective verification of use rather than self-report. And measurement of the proposed growth-factor mechanism in people rather than rodents [1].

The noribogaine entry covers the metabolite timeline, and the evidence overview places the follow-up data beside the rest.

Frequently asked questions

How long does ibogaine stay in the body?

More than ninety per cent of a dose is eliminated within twenty-four hours [2]. Noribogaine, the compound the body makes from it, persists longer and does not decline significantly within the first day [2].

How long is someone at cardiac risk?

QT prolongation typically lasts more than twenty-four hours and in some cases more than a week [2]. Reported deaths have occurred up to seventy-six hours after intake [2].

Do the benefits last a year?

Two uncontrolled follow-ups report changes holding at twelve months [3][4], one of them a preprint that has not been peer reviewed [4]. Both lost participants along the way.

How soon can someone travel home?

That is a medical decision rather than a scheduling one. The QT interval can remain prolonged after the drug has cleared, in some reported cases beyond a week [2], and six of fourteen patients in one monitored cohort were still above 450 milliseconds past twenty-four hours [7]. Insomnia lasting about 72 hours is also common [6].

Does a second treatment extend the effect?

In the Brazilian review, median abstinence was 8.4 months after multiple treatments against 5.5 after one [5]. A retrospective design cannot separate an accumulating effect from the possibility that people who returned were those the first treatment had helped.